Pharmaceutical companies that manufacture GLP-1 drugs have increasingly promoted telehealth providers that prescribe the popular treatments. A deal announced this week is expected to further complicate one of those relationships.
Eli Lilly has listed a telehealth company called Counsel Health among the providers available to patients seeking a GLP-1 prescription.
On Tuesday, Counsel said it would be acquired by Oura, the smart-ring maker. The deal would give Counsel clinicians access to data collected through the ring, enabling them to help customers interpret the information and diagnose or treat conditions. Experts say the acquisition raises conflict-of-interest questions for Eli Lilly.
Also Read
- A Common Hospital Antibiotic Linked to Rare ‘I Am Dead’ Delusion—and to Delirium in a Major Trial
- Australia Reports 25% Decline in Gabapentinoid Prescriptions and 50% Drop in Overdose Rates
- CDC Terminates Direct Community Grants: 11 Texas HIV Prevention Groups Face $29.2 Million Funding Loss
- FDA Revokes Methylene Chloride Approval for Produce Inks and Color Additive Solvents
